Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-11-07Actual
Enrollment · participants75Actual
Source updated2025-03-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.